The addition of extended-release niacin–laropiprant to statin-based low-density lipoprotein (LDL) cholesterol–lowering therapy in patients with atherosclerotic vascular disease did not significantly reduce the risk of major vascular events but did increase the risk of serious adverse events, a randomized trial of 25,673 participants concluded. During a median follow-up period of 3.9 years, 2 grams of niacin with 40 mg of the antiflushing agent laropiprant (Tredaptive) did lower the LDL cholesterol level and raise the high-density lipoprotein (HDL) cholesterol level, but had no significant effect on the incidence of major vascular events. Niacin–laropiprant was associated with an increased incidence of disturbances in diabetes control and with an increased incidence of diabetes diagnoses as well as increases in serious adverse events associated with the gastrointestinal system, musculoskeletal system, skin, and unexpectedly, infection and bleeding. Source: http://www.nejm.org/一项包括25,673参与者的随机临床试验得出结论, 动脉粥样硬化患者在他汀类药物降低密度脂蛋白（LDL）胆固醇治疗基础上添加缓释烟酸和防潮红药laropiprant并没有显著减少严重心血管病的风险，反增加严重不良反应的风险。在平均随访3.9年中, 2克烟酸和40毫克的防潮红药laropiprant（Tredaptive）的确降低了LDL胆固醇水平并且提高高密度脂蛋白（HDL）胆固醇水平，但并没有显著影响严重心血管病的发生率。烟酸和laropiprant干扰糖尿病控制, 使糖尿病的发病率增加，以及增加胃肠系统，肌肉骨骼系统和皮肤的严重不良反应，并出乎意料的增加与感染和出血相关的严重不良反应。来源：http://www.nejm.org/
